PL
RIGL icon

Parkwood LLC’s Rigel Pharmaceuticals RIGL Stock Holding History

Parkwood LLC’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,536
Closed -$30K – 514
2014
Q3 		$30K Buy
+1,536
New +$43.4K 0.01% 276
2014
Q1 		– Sell
-4,065
Closed -$116K – 379
2013
Q4 		$116K Buy
+4,065
New +$119K 0.03% 338

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Parkwood LLC's RIGL Position: Q4 2014 in Review

Parkwood LLC sold out of Rigel Pharmaceuticals (RIGL) in Q4 2014, closing a stake of 1,536 shares — an estimated $30K sold.

Parkwood LLC first reported a position in RIGL in Q4 2013 and held it in 2 quarters. The position peaked at $116K in Q4 2013. 96 funds tracked by Wall St. Rank hold RIGL as of Q4 2014.

  • Parkwood LLC reported no remaining Rigel Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Parkwood LLC sold 1,536 Rigel Pharmaceuticals shares in Q4 2014, an estimated $30K.
  • Parkwood LLC first reported a position in Rigel Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Parkwood LLC's Rigel Pharmaceuticals position peaked at $116K in Q4 2013.
  • 96 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2014.

Based on Parkwood LLC's 13F filing for Q4 2014, filed 11 Feb 2015.